Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maint...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-023-00948-6 |
| _version_ | 1797736420201201664 |
|---|---|
| author | Melinda J. Gooderham Andrew E. Pink Eric L. Simpson Jonathan I. Silverberg Erman Güler Melissa Watkins |
| author_facet | Melinda J. Gooderham Andrew E. Pink Eric L. Simpson Jonathan I. Silverberg Erman Güler Melissa Watkins |
| author_sort | Melinda J. Gooderham |
| collection | DOAJ |
| description | Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maintenance dose. This review summarizes the efficacy and safety of abrocitinib 100 mg once daily for patients with moderate-to-severe AD based on data from the pivotal phase 3 studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical program, JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871), JADE COMPARE (NCT03720470), JADE TEEN (NCT03796676), and JADE REGIMEN (NCT03627767). Preliminary long-term efficacy and safety data are also summarized from the long-term extension study JADE EXTEND (NCT03422822). Expert opinion on use of abrocitinib 100 mg once daily in clinical practice is provided. In addition to efficacy, the decision to use abrocitinib for the treatment of AD should allow for individual patient factors such as age, comorbidities, previous therapy, quality of life, and treatment tolerability, and involve shared decision-making between the patient and clinician. |
| first_indexed | 2024-03-12T13:13:35Z |
| format | Article |
| id | doaj.art-910ab250dacb46cba12498d99a103afa |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-03-12T13:13:35Z |
| publishDate | 2023-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-910ab250dacb46cba12498d99a103afa2023-08-27T11:09:57ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722023-07-011391893190710.1007/s13555-023-00948-6Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical PracticeMelinda J. Gooderham0Andrew E. Pink1Eric L. Simpson2Jonathan I. Silverberg3Erman Güler4Melissa Watkins5SKiN Centre for Dermatology, Peterborough, and Queen’s UniversitySt John’s Institute of Dermatology, King’s College London and Guy’s and St Thomas’ NHS Foundation TrustDermatology Department, Oregon Health & Science UniversityDermatology Department, The George Washington University School of Medicine and Health SciencesPfizer Inc.Pfizer Inc.Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maintenance dose. This review summarizes the efficacy and safety of abrocitinib 100 mg once daily for patients with moderate-to-severe AD based on data from the pivotal phase 3 studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical program, JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871), JADE COMPARE (NCT03720470), JADE TEEN (NCT03796676), and JADE REGIMEN (NCT03627767). Preliminary long-term efficacy and safety data are also summarized from the long-term extension study JADE EXTEND (NCT03422822). Expert opinion on use of abrocitinib 100 mg once daily in clinical practice is provided. In addition to efficacy, the decision to use abrocitinib for the treatment of AD should allow for individual patient factors such as age, comorbidities, previous therapy, quality of life, and treatment tolerability, and involve shared decision-making between the patient and clinician.https://doi.org/10.1007/s13555-023-00948-6AbrocitinibClinical practiceFlexible dosingJAK1-selective inhibitorModerate-to-severe atopic dermatitisOral systemic therapy |
| spellingShingle | Melinda J. Gooderham Andrew E. Pink Eric L. Simpson Jonathan I. Silverberg Erman Güler Melissa Watkins Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice Dermatology and Therapy Abrocitinib Clinical practice Flexible dosing JAK1-selective inhibitor Moderate-to-severe atopic dermatitis Oral systemic therapy |
| title | Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice |
| title_full | Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice |
| title_fullStr | Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice |
| title_full_unstemmed | Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice |
| title_short | Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice |
| title_sort | abrocitinib 100 mg once daily for moderate to severe atopic dermatitis a review of efficacy and safety and expert opinion on use in clinical practice |
| topic | Abrocitinib Clinical practice Flexible dosing JAK1-selective inhibitor Moderate-to-severe atopic dermatitis Oral systemic therapy |
| url | https://doi.org/10.1007/s13555-023-00948-6 |
| work_keys_str_mv | AT melindajgooderham abrocitinib100mgoncedailyformoderatetosevereatopicdermatitisareviewofefficacyandsafetyandexpertopiniononuseinclinicalpractice AT andrewepink abrocitinib100mgoncedailyformoderatetosevereatopicdermatitisareviewofefficacyandsafetyandexpertopiniononuseinclinicalpractice AT ericlsimpson abrocitinib100mgoncedailyformoderatetosevereatopicdermatitisareviewofefficacyandsafetyandexpertopiniononuseinclinicalpractice AT jonathanisilverberg abrocitinib100mgoncedailyformoderatetosevereatopicdermatitisareviewofefficacyandsafetyandexpertopiniononuseinclinicalpractice AT ermanguler abrocitinib100mgoncedailyformoderatetosevereatopicdermatitisareviewofefficacyandsafetyandexpertopiniononuseinclinicalpractice AT melissawatkins abrocitinib100mgoncedailyformoderatetosevereatopicdermatitisareviewofefficacyandsafetyandexpertopiniononuseinclinicalpractice |